Safety concerns associated with therapeutic intervention(s) and immunizations can be detected, analyzed, and minimized only through early identification and having proper risk minimization measures throughout the life cycle of a drug. Researchers face multiple challenges while designing the right strategies for early detection of safety signals. Safety concerns can arise throughout the lifecycle of a drug, broadly divided into pre-market clinical development and post marketing surveillance activities. The pre-market safety assessments cannot reveal all safety concerns due to the limited an ..read more

The healthcare landscape is a dynamic ecosystem, constantly growing with new drugs, cosmetics, nutraceuticals, and medical devices. The global healthcare market size including drugs, cosmetics, nutraceuticals, and devices is anticipated to be in the region of $10 trillion by 2025 with a broad average CAGR of 5%.  This rapid growth and innovation, while exciting, necessitates robust safety measures. Multivigilance, the comprehensive, end-to-end monitoring of a product’s safety profile, plays a critical role in safeguarding patient well-being.  This blog dips into the challenges curr ..read more

In the past few years, the domain of Pharmacovigilance (PV) (incl. Cosmetovigilance and Materiovigilance) has moved from a point where automation was being explored to automation becoming an imperative.  The primary reasons for this change are simply the numbers. It is estimated that the number of Adverse Events (AEs) being reported has been increasing by 30 % on an average since 2019. Large pharma companies, especially the ones with vaccines (which is almost all of them), are having to process AEs upwards of 500k per year, costing the companies in tens of millions of dollars. Even Small ..read more

In the rapidly evolving landscape of pharmacovigilance (PV), ensuring patient safety and health outcomes is non-negotiable. With the surge in post-marketing drug surveillance and safety concerns, literature monitoring has become pivotal. Further, with the AI revolution, the race to transform various aspects of Healthcare Management is at its peak. In the context of PV, let us explore the top 5 reasons to adopt an AI-powered tool for Literature Surveillance.  1. Efficient Article Search and Ingestion:  An Intelligent Search Engine powered by AI can make the article search and ingest ..read more

The challenges of Safety Vigilance in Pharma, Cosmetics, Devices, Vaccines and Nutraceuticals are creating a compelling need for a platform approach to address spiralling costs and ensure compliance.  A Business Process-as-a-Service (BPaaS) model is finding increasing interest among industry players whereby companies can get the best of modern technologies such as AI/ML, Secure Cloud Services and Analytics in a cost and time effective manner, while improving compliance to regulations related to patient safety and privacy.  The key drivers for a Safety Vigilance BPaaS solution could ..read more

Navigating the Tsunami of Data According to a recent report by Arcadia Approximately 30% of the world’s data volume is generated by the healthcare industry, with the compound annual growth rate of healthcare data forecasted to reach 36% by 2025.  The Life Sciences (LS) industry is generating and accumulating data at an unprecedented rate. This article highlights some of the Drivers, Impacts and Possible Solutions to meet this challenge and leverage maximum value from this immense opportunity.    Drivers of the Data Boom The key drivers fuelling the explosive growth of Life ..read more

In the highly regulated landscape of pharmacovigilance (PV), ensuring patient safety and health outcomes is paramount. With increasing focus on post-marketing drug surveillance and drug safety, literature monitoring has taken a center spot in PV. Literature surveillance involves monitoring scientific literature on adverse drug reactions and safety concerns related to pharmaceutical products. Challenges in Medical Literature Monitoring According to a report by Elsevier, literature is quoted as the fourth largest source for Adverse Events Reporting. As per the SJR dataset, more than 1.4 million ..read more

The pharmaceutical industry is advancing at an unprecedented pace, with new drugs and therapies continually emerging to improve patient outcomes. Yet, the critical focus on patient safety has never been more intense. For small and medium-sized pharmaceutical companies, this presents both an opportunity and a challenge. The opportunity lies in delivering innovative and safe medicines to the market, while the challenge is to ensure that safety practices are on par with the industry giants. This is where drug safety automation, particularly with the likes of DF mSafety AI, can transform the land ..read more

Introduction Identifying adverse events from medical literature is one of the key tasks in pharmacovigilance (PV). It is also one of the most complex.  In pharmacovigilance, patient safety and regulatory compliance are paramount, and correctly identifying adverse events from the vast ocean of medical literature is akin to finding a needle in a haystack. Let’s delve into the intricacies of this process, understand the challenges it presents, and explore how DF Literature Monitor is revolutionizing the landscape. The Overwhelming Volume of Information  The first challenge is the sheer ..read more

In the fast-evolving landscape of pharmacovigilance, staying ahead of potential adverse events (AEs) and ensuring patient safety is paramount. Manual processes for literature monitoring are time-consuming and prone to oversight, which is why Datafoundry’s DF Literature Monitor is a game-changer. Let us delve into one of the groundbreaking features that is transforming the way pharmacovigilance experts work: Automated Multi-Source Articles Import.  Embracing Automation for Enhanced Vigilance  Gone are the days of laborious article searches across multiple databases. With the Automate ..read more